1
Yale Digestive Disorders
Yale New Haven Hospital
20 York Street
New Haven, CT 06510
1 of 3
- Yale Digestive DisordersYale New Haven Hospital20 York StreetNew Haven, CT 06510
- Old Saybrook Medical Center633 Middlesex TurnpikeOld Saybrook, CT 06475
- 8 Devine StreetNorth Haven, CT 06473
Wajahat Mehal, MD, DPhil
Obesity Medicine, Gastroenterology, Hepatology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Gastroenterology, Internal Medicine
, and Transplant Hepatology
Biography
Wajahat Mehal MD, DPhil, is Professor of Medicine in Digestive Diseases, and Director of the Yale Fatty Liver Disease Program and the Yale Metabolic Health and Weight Loss Program.
He cares for patients with all liver diseases in the outpatient and inpatient setting, and particularly focuses on the areas of non-alcoholic and alcoholic fatty liver disease. He is also trained in obesity medicine and endobariatrics, managing patients by providing the full range of weight loss interventions, which include nutrition, medications, meal replacement, endobariatrics, and referrals to bariatric surgery.
In addition, he has an active NIH-funded translational research program in the areas of inflammation and fibrosis.
Titles
- Professor of Medicine (Digestive Diseases)
- Director of Yale Weight Loss Program
- Director of Yale Fatty Liver Disease Program
Education & Training
- FellowYale New Haven Hospital (2001)
- ResidentYale New Haven Hospital (1996)
- DPhilUniversity of Oxford (1993)
- MDUniversity of Oxford (1990)
Additional Information
Honors & Recognitions
- Fellow: American Association for the Study of Liver Diseases (2021)
Publications
- Lokeshwar S, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Mehal W, Brito J, Renzulli J, Leapman M. The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy. BMC Urology 2024, 24: 102. PMID: 38702664, PMCID: PMC11067086, DOI: 10.1186/s12894-024-01483-y.
- Taiwo M, Huang E, Pathak V, Bellar A, Welch N, Dasarathy J, Streem D, McClain C, Mitchell M, Barton B, Szabo G, Dasarathy S, Schaefer E, Luther J, Day L, Ouyang X, Suyavaran A, Mehal W, Jacobs J, Goodman R, Rotroff D, Nagy L. Complement protein signatures in patients with alcohol-associated hepatitis. JCI Insight 2024, 9 PMID: 38573776, DOI: 10.1172/jci.insight.174127.
- Do A, Ilagan-Ying Y, Deng Y, Banini B, Lim J, Mehal W. S1581 Assessing the Effectiveness of Incorporating Weight Management Treatments Into a Fatty Liver Disease Program. The American Journal Of Gastroenterology 2023, 118: s1193-s1194. DOI: 10.14309/01.ajg.0000955964.73046.7b.
- Kaffe E, Tisi A, Magkrioti C, Aidinis V, Mehal W, Flavell R, Maccarrone M. Bioactive signalling lipids as drivers of chronic liver diseases. Journal Of Hepatology 2023, 80: 140-154. PMID: 37741346, DOI: 10.1016/j.jhep.2023.08.029.
- Mehal W. Mechanisms of liver fibrosis in metabolic syndrome. EGastroenterology 2023, 1: e100015. PMID: 37946713, PMCID: PMC10634657, DOI: 10.1136/egastro-2023-100015.
- Kaffe E, Roulis M, Zhao J, Qu R, Sefik E, Mirza H, Zhou J, Zheng Y, Charkoftaki G, Vasiliou V, Vatner D, Mehal W, AlcHepNet, Kluger Y, Flavell R. Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions. Cell 2023, 186: 3793-3809.e26. PMID: 37562401, PMCID: PMC10544749, DOI: 10.1016/j.cell.2023.07.017.
- Li B, Li Y, Zhou H, Xu Y, Cao Y, Cheng C, Peng J, Li H, Zhang L, Su K, Xu Z, Hu Y, Lu J, Lu Y, Qian L, Wang Y, Zhang Y, Liu Q, Xie Y, Guo S, Mehal W, Yu D. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma. Hepatology 2023, 79: 289-306. PMID: 37540187, PMCID: PMC10789383, DOI: 10.1097/hep.0000000000000553.
- Zahrawi F, Fathma S, Mehal W, Banini B. Pharmacologic Management of Obesity after Liver Transplantation: A Critical Review. Annals Of Gastroenterology And Digestive Disorders 2023, 6: 17-25. PMID: 38098758, PMCID: PMC10719957.
- Arumugam S, Li B, Boodapati S, Nathanson M, Sun B, Ouyang X, Mehal W. Mitochondrial DNA and the STING pathway are required for hepatic stellate cell activation. Hepatology 2023, 78: 1448-1461. PMID: 37013923, PMCID: PMC10804318, DOI: 10.1097/hep.0000000000000388.
- New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disordersJamshed F, Dashti F, Ouyang X, Mehal W, Banini B. New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders. World Journal Of Gastroenterology 2023, 29: 1824-1837. PMID: 37032732, PMCID: PMC10080697, DOI: 10.3748/wjg.v29.i12.1824.
- Dashti F, Jamshed F, Ouyang X, Mehal W, Banini B. Digoxin as an emerging therapy in noncardiac diseases. Trends In Pharmacological Sciences 2022, 44: 199-203. PMID: 36396496, DOI: 10.1016/j.tips.2022.10.002.
- Ilagan-Ying Y, Schwartz A, Park E, Bollinger B, Ying L, Mehal W, Do A. S1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating Obesity Medicine for Treatment of Nonalcoholic Fatty Liver Disease. The American Journal Of Gastroenterology 2022, 117: e1043-e1044. DOI: 10.14309/01.ajg.0000862452.53915.0f.
- Ilagan-Ying Y, Valido K, Chehayeb R, Bollinger B, Mehal W, Do A. S1345 Weight Loss Outcomes With and Without Diabetes in Patients With NAFLD in a Specialty Fatty Liver Disease Program. The American Journal Of Gastroenterology 2022, 117: e967-e968. DOI: 10.14309/01.ajg.0000862020.76034.41.
- Ilagan-Ying Y, Cotter R, Bollinger B, Mehal W, Do A. S1358 Nonalcoholic Fatty Liver Disease Outcomes in Patients With Comorbid Psychiatric Disorders Improved by Integrated Medical Weight Management and Hepatology Clinic Care. The American Journal Of Gastroenterology 2022, 117: e975-e976. DOI: 10.14309/01.ajg.0000862072.84358.84.
- Batisti J, Mehal W. Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient. Current Transplantation Reports 2020, 7: 332-339. DOI: 10.1007/s40472-020-00303-0.
- Mankash M, Kelly M, Duffy A, Mehal W, Do A. S1189 Incorporation of Obesity Medicine Into the Care of Patients With Nonalcoholic Fatty Liver Disease: 1-Year Interim Results. The American Journal Of Gastroenterology 2020, 115: s595-s595. DOI: 10.14309/01.ajg.0000706804.10023.a3.
- Mankash M, Kelly M, Mehal W, Do A. S1016 Tolerance and Safety of Meal Replacement Program in Nonalcoholic Steatohepatitis With Fibrosis and Cirrhosis: A Case Series. The American Journal Of Gastroenterology 2020, 115: s518-s519. DOI: 10.14309/01.ajg.0000706112.69854.c1.
- Mankash M, Yousaf M, Duffy A, Mehal W, Do A. S1015 Bariatric Surgery Can Be Performed Safely at Yale-New Haven Hospital in Patients With Cirrhosis. The American Journal Of Gastroenterology 2020, 115: s518-s518. DOI: 10.14309/01.ajg.0000706108.48385.f8.
- Do A, Ilagan-Ying Y, Mehal W. Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports 2019, 18: 444-454. DOI: 10.1007/s11901-019-00498-6.
- Yousaf M, Chaudhary F, Mehal W. The impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Gastroenterology & Hepatology Open Access 2019, 10: 262-266. DOI: 10.15406/ghoa.2019.10.00392.
- Do A, Kuszewski EJ, Langberg K, Mehal W. Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. Hepatology 2019, 70: 1443-1456. PMID: 30991446, PMCID: PMC6783325, DOI: 10.1002/hep.30658.
- Mankash M, Kelly M, Dean J, Duffy A, Mehal W, Do A. 1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model. The American Journal Of Gastroenterology 2019, 114: s599-s599. DOI: 10.14309/01.ajg.0000593756.22484.ae.
- Vijay G, Hu C, Peng J, Garcia-Martinez I, Hoque R, Verghis RM, Ma Y, Mehal W, Shawcross DL, Wen L. Ammonia-Induced Brain Edema Requires Macrophage and T Cell Expression of Toll-Like Receptor 9. Cellular And Molecular Gastroenterology And Hepatology 2019, 8: 609-623. PMID: 31401214, PMCID: PMC6889059, DOI: 10.1016/j.jcmgh.2019.08.002.
- Mehal W, Dioletis E, Paiva R, Secor E, Weiss T, Fields M, Ali A. The Fermented Soy Beverage Q-CAN® Plus Induces Changes in the Oral and Intestinal Microbiome (P20-018-19). Current Developments In Nutrition 2019, 3: nzz040.p20-018-19. PMCID: PMC6574065, DOI: 10.1093/cdn/nzz040.p20-018-19.
- Mehal W, Secor E, Weiss T, Fields M, Leapman M, Ali A. Isoflavone Stability Quality Control Assessment of Q-CAN® Plus, a Novel Fermented Soy Beverage (P12-034-19). Current Developments In Nutrition 2019, 3: 3013530. PMCID: PMC6574992, DOI: 10.1093/cdn/nzz035.p12-034-19.
- Mehal W, Suyavaran A, Dioletis E, Paiva R, Weiss T, Fields M, Ouyang X. Reduction in Serum Levels of Inflammatory Cytokines in Subjects Consuming the Fermented Soy Beverage Q-CAN® Plus (P19-010-19). Current Developments In Nutrition 2019, 3: nzz049.p19-010-19. PMCID: PMC6579392, DOI: 10.1093/cdn/nzz049.p19-010-19.
- Mehal W, Suyavaran A, Dioletis E, Paiva R, Secor E, Weiss T, Fields M, Ouyang X, Ali A. Hematology Safety Data for the Fermented Soy Beverage Q-CAN® Plus (P12-033-19). Current Developments In Nutrition 2019, 3: 3013529. PMCID: PMC6574472, DOI: 10.1093/cdn/nzz035.p12-033-19.
- Mehal W, Dioletis E, Paiva R, Secor E, Weiss T, Fields M, Ouyang X, Ali A. Reduction in Serum Cholesterol in Subjects Consuming the Fermented Soy Beverage Q-CAN® Plus (P06-118-19). Current Developments In Nutrition 2019, 3: nzz031.p06-118-19. PMCID: PMC6576748, DOI: 10.1093/cdn/nzz031.p06-118-19.
- Ouyang X, Mehal W. 894 - Digoxin Protects from Alcoholic Hepatitis and Inhibits TGF-B Induced Fibrotic Response. Gastroenterology 2018, 154: s-1109. DOI: 10.1016/s0016-5085(18)33689-8.
- Chen Y, Yousaf M, Mehal W. Role of sterile inflammation in fatty liver diseases. Liver Research 2018, 2: 21-29. DOI: 10.1016/j.livres.2018.02.003.
- Ouyang X, Han SN, Zhang JY, Dioletis E, Nemeth BT, Pacher P, Feng D, Bataller R, Cabezas J, Stärkel P, Caballeria J, Pongratz RL, Cai SY, Schnabl B, Hoque R, Chen Y, Yang WH, Garcia-Martinez I, Wang FS, Gao B, Torok NJ, Kibbey RG, Mehal WZ. Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis. Cell Metabolism 2018, 27: 339-350.e3. PMID: 29414684, PMCID: PMC5806149, DOI: 10.1016/j.cmet.2018.01.007.
- Vijay G, Hu C, Peng J, Martinez I, Hoque R, Zhang X, Ma Y, Mehal W, Shawcross D, Wen L. Ammonia Mediated Brain-oedema and Immune Dysfunction is Mediated by Toll-like Receptor (TLR) 9. Journal Of Clinical And Experimental Hepatology 2017, 7: s2-s3. DOI: 10.1016/j.jceh.2017.01.004.
- Vijay G, Hu C, Peng J, Martinez I, Hoque R, Zhang X, Ma Y, Mehal W, Shawcross D, Wen L. THU-418 Ammonia-Induced Brain Oedema and Immune Dysfunction is Mediated by Toll-Like Receptor 9 (TLR9). Journal Of Hepatology 2016, 64: s314. DOI: 10.1016/s0168-8278(16)00420-7.
- Farooq A, Farooq A, Mehal W. Aspartate a New Treatment Modality in the Treatment of Acute Liver Failure and Actiminophen-Induced Toxicity. The American Journal Of Gastroenterology 2015, 110: s895. DOI: 10.14309/00000434-201510001-02147.
- Mehal W, Schuppan D. Antifibrotic Therapies in the Liver. Seminars In Liver Disease 2015, 35: 184-198. PMID: 25974903, PMCID: PMC5743222, DOI: 10.1055/s-0035-1550055.
- Ouyang X, Zhang J, Feng D, Cai S, Protiva P, Garcia-Martinez I, Wang F, Gao B, Mehal W. Su1058 Low Dose Digoxin Protects From NASH and Alcoholic Hepatitis in Mice by Inhibiting Inflammasome Activity and Mitochondrial ROS Production. Gastroenterology 2015, 148: s-1052. DOI: 10.1016/s0016-5085(15)33588-5.
- Garcia-Martinez I, Santoro N, Chen Y, Ouyang X, Caprio S, Coffman R, Candia A, Mehal W. 237 Humans and Mice With NASH Have Increased Plasma Levels of TLR9 Ligand, and a TLR7/9 Bifunctional Antagonist Reduces NASH in Mice. Gastroenterology 2015, 148: s-974. DOI: 10.1016/s0016-5085(15)33328-x.
- Ghani A, Mehal W, Ali A. Food Reactivity on the ALCAT Leukocyte Activation Test Is Associated with Upregulation of CD11b on T Cells. Journal Of Alternative And Complementary Medicine 2014, 20: a35-a36. DOI: 10.1089/acm.2014.5089.abstract.
- Mehal WZ. Who is the scientist in bio-medical research, the author or the reviewer? Frontiers In Pharmacology 2014, 5: 50. PMID: 24723888, PMCID: PMC3972448, DOI: 10.3389/fphar.2014.00050.
- Hoque R, Farooq A, Ghani A, Gorelick F, Mehal WZ. Lactate Reduces Liver and Pancreatic Injury in Toll-Like Receptor– and Inflammasome-Mediated Inflammation via GPR81-Mediated Suppression of Innate Immunity. Gastroenterology 2014, 146: 1763-1774. PMID: 24657625, PMCID: PMC4104305, DOI: 10.1053/j.gastro.2014.03.014.
- Ouyang X, Ghani A, Malik A, Wilder T, Colegio OR, Flavell RA, Cronstein BN, Mehal WZ. Adenosine is required for sustained inflammasome activation via the A2A receptor and the HIF-1α pathway. Nature Communications 2013, 4: 2909. PMID: 24352507, PMCID: PMC3895487, DOI: 10.1038/ncomms3909.
- Gao B, Friedman S, Mehal W. The Immunopathogenesis of Cirrhosis. 2013, 413-424. DOI: 10.1007/978-3-319-02096-9_28.
- Mehal WZ. The Gordian Knot of dysbiosis, obesity and NAFLD. Nature Reviews Gastroenterology & Hepatology 2013, 10: 637-644. PMID: 23958600, DOI: 10.1038/nrgastro.2013.146.
- Kubes P, Mehal WZ. Sterile Inflammation in the Liver. Gastroenterology 2012, 143: 1158-1172. PMID: 22982943, DOI: 10.1053/j.gastro.2012.09.008.
- Mehal W, Imaeda A. Cell Death and Fibrogenesis. Seminars In Liver Disease 2010, 30: 226-231. PMID: 20665375, PMCID: PMC3219753, DOI: 10.1055/s-0030-1255352.
- Sohail M, Malik A, Hoque R, Mehal W. 239 P2X7 Receptor Activation up-Stream of the NLRP3 Inflammasome is Required for APAP Hepatotoxicity in Mice. Gastroenterology 2010, 138: s-781. DOI: 10.1016/s0016-5085(10)63599-8.
- Sohail M, Husain S, Hoque R, Malik A, Shah A, Mehal W. M1674 Caspase-1 and TLR-7,9 Signaling are Required for Cerulein Pancreatitis. Gastroenterology 2010, 138: s-827. DOI: 10.1016/s0016-5085(10)63811-5.
- Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M, Sutterwala FS, Flavell RA, Mehal WZ. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. Journal Of Clinical Investigation 2009, 119: 305-314. PMID: 19164858, PMCID: PMC2631294, DOI: 10.1172/jci35958.
- Sohail M, Watanabe A, Mahmood S, Hashmi A, Hakim W, Mehal W. M1578 Adenosine Induces Loss of Actin Stress Fibers and Inhibits Contraction in Hepatic Stellate Cells Via Rho Inhibition. Gastroenterology 2008, 134: a-797. DOI: 10.1016/s0016-5085(08)63725-7.
- Mahmood S, Watanabe A, Sohail M, Flavell R, Mehal W. 56 Aacetaminophen Hepatotoxicity Is Dependent On TLR9 and Can Be Reduced By a TLR9 Antagonist. Gastroenterology 2008, 134: a-752. DOI: 10.1016/s0016-5085(08)63514-3.
- Imaeda A, Sutterwala F, Watanabe A, Mahmood S, Sohail M, Flavell R, Mehal W. 467 Aspirin Blocks Acetaminophen Induced Hepatotoxicity and Mortality in Mice - Dependent On the ASC/Caspase-1 Inflammasome. Gastroenterology 2008, 134: a-767. DOI: 10.1016/s0016-5085(08)63581-7.
- Mohamadnejad M, Sohail M, Swenson E, Mehal W. T1773 Adenosine Inhibits Hepatocyte Growth Factor Induced Chemotaxis in Mesenchymal Stem Cells. Gastroenterology 2008, 134: a-819. DOI: 10.1016/s0016-5085(08)63829-9.
- Mehal W, Friedman S. The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis. 2007, 111-121. DOI: 10.1007/978-1-59745-518-3_10.
- Mehal W. The Clinician's Guide to Liver Disease. Journal Of Clinical Gastroenterology 2006, 40: 564. DOI: 10.1097/00004836-200607000-00027.
- Qamar A, Sheikh S, Inayat I, Mehal W. 213 Leptin protects stellate cells, but not hepatocytes, from CD95 mediated apoptosis. Hepatology 2003, 38: 259. DOI: 10.1016/s0270-9139(03)80256-2.
- Mehal W, Azzaroli F, Crispe I. Antigen Presentation by Liver Cells Controls Intrahepatic T Cell Trapping, Whereas Bone Marrow-Derived Cells Preferentially Promote Intrahepatic T Cell Apoptosis. The Journal Of Immunology 2001, 167: 667-673. PMID: 11441069, DOI: 10.4049/jimmunol.167.2.667.
- Dao T, Exley M, Mehal W, Tahir S, Snapper S, Taniguchi M, Balk S, Crispe I. Involvement of CD1 in Peripheral Deletion of T Lymphocytes Is Independent of NK T Cells. The Journal Of Immunology 2001, 166: 3090-3097. PMID: 11207260, DOI: 10.4049/jimmunol.166.5.3090.
- Mehal W, Azzaroli F, Crispe I. Immunology of the healthy liver: Old questions and new insights. Gastroenterology 2001, 120: 250-260. PMID: 11208734, DOI: 10.1053/gast.2001.20947.
- Theise N, Krause D, Mehal W, Illei P. Reply. Hepatology 2000, 32: 1181. DOI: 10.1016/s0270-9139(00)80044-0.
- Crispe I, Dao T, Klugewitz K, Mehal W, Metz D. The liver as a site of T‐cell apoptosis: graveyard, or killing field? Immunological Reviews 2000, 174: 47-62. PMID: 10807506, DOI: 10.1034/j.1600-0528.2002.017412.x.
- Mehal W, Juedes A, Crispe I. Selective retention of activated CD8+ T cells by the normal liver. The Journal Of Immunology 1999, 163: 3202-10. PMID: 10477588, DOI: 10.4049/jimmunol.163.6.3202.
- Conte H, Chen Y, Mehal W, Phil D, Scinto J, Quagliarello V. A prognostic rule for elderly patients admitted with community-acquired pneumonia. The American Journal Of Medicine 1999, 106: 20-28. PMID: 10320113, DOI: 10.1016/s0002-9343(98)00369-6.
- Dao T, Mehal W, Crispe I. IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. The Journal Of Immunology 1998, 161: 2217-22. PMID: 9725214, DOI: 10.4049/jimmunol.161.5.2217.
- Mehal W, Crispe I. TCR ligation on CD8+ T cells creates double-negative cells in vivo. The Journal Of Immunology 1998, 161: 1686-93. PMID: 9712032, DOI: 10.4049/jimmunol.161.4.1686.
- Crispe I, Mehal W. Strange brew: T cells in the liver. Trends In Immunology 1996, 17: 522-525. PMID: 8961629, DOI: 10.1016/s0167-5699(96)80906-6.
Locations
1
Yale Digestive Disorders
Yale New Haven Hospital
20 York Street
New Haven, CT 06510
1 of 3
- Yale Digestive DisordersYale New Haven Hospital20 York StreetNew Haven, CT 06510
- Old Saybrook Medical Center633 Middlesex TurnpikeOld Saybrook, CT 06475
- 8 Devine StreetNorth Haven, CT 06473
Biography
Wajahat Mehal MD, DPhil, is Professor of Medicine in Digestive Diseases, and Director of the Yale Fatty Liver Disease Program and the Yale Metabolic Health and Weight Loss Program.
He cares for patients with all liver diseases in the outpatient and inpatient setting, and particularly focuses on the areas of non-alcoholic and alcoholic fatty liver disease. He is also trained in obesity medicine and endobariatrics, managing patients by providing the full range of weight loss interventions, which include nutrition, medications, meal replacement, endobariatrics, and referrals to bariatric surgery.
In addition, he has an active NIH-funded translational research program in the areas of inflammation and fibrosis.
Titles
- Professor of Medicine (Digestive Diseases)
- Director of Yale Weight Loss Program
- Director of Yale Fatty Liver Disease Program
Education & Training
- FellowYale New Haven Hospital (2001)
- ResidentYale New Haven Hospital (1996)
- DPhilUniversity of Oxford (1993)
- MDUniversity of Oxford (1990)
Additional Information
Honors & Recognitions
- Fellow: American Association for the Study of Liver Diseases (2021)
Publications
- Lokeshwar S, Ali A, Weiss T, Reynolds J, Shuch B, Ferencz T, Kyriakides T, Mehal W, Brito J, Renzulli J, Leapman M. The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy. BMC Urology 2024, 24: 102. PMID: 38702664, PMCID: PMC11067086, DOI: 10.1186/s12894-024-01483-y.
- Taiwo M, Huang E, Pathak V, Bellar A, Welch N, Dasarathy J, Streem D, McClain C, Mitchell M, Barton B, Szabo G, Dasarathy S, Schaefer E, Luther J, Day L, Ouyang X, Suyavaran A, Mehal W, Jacobs J, Goodman R, Rotroff D, Nagy L. Complement protein signatures in patients with alcohol-associated hepatitis. JCI Insight 2024, 9 PMID: 38573776, DOI: 10.1172/jci.insight.174127.
- Do A, Ilagan-Ying Y, Deng Y, Banini B, Lim J, Mehal W. S1581 Assessing the Effectiveness of Incorporating Weight Management Treatments Into a Fatty Liver Disease Program. The American Journal Of Gastroenterology 2023, 118: s1193-s1194. DOI: 10.14309/01.ajg.0000955964.73046.7b.
- Kaffe E, Tisi A, Magkrioti C, Aidinis V, Mehal W, Flavell R, Maccarrone M. Bioactive signalling lipids as drivers of chronic liver diseases. Journal Of Hepatology 2023, 80: 140-154. PMID: 37741346, DOI: 10.1016/j.jhep.2023.08.029.
- Mehal W. Mechanisms of liver fibrosis in metabolic syndrome. EGastroenterology 2023, 1: e100015. PMID: 37946713, PMCID: PMC10634657, DOI: 10.1136/egastro-2023-100015.
- Kaffe E, Roulis M, Zhao J, Qu R, Sefik E, Mirza H, Zhou J, Zheng Y, Charkoftaki G, Vasiliou V, Vatner D, Mehal W, AlcHepNet, Kluger Y, Flavell R. Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions. Cell 2023, 186: 3793-3809.e26. PMID: 37562401, PMCID: PMC10544749, DOI: 10.1016/j.cell.2023.07.017.
- Li B, Li Y, Zhou H, Xu Y, Cao Y, Cheng C, Peng J, Li H, Zhang L, Su K, Xu Z, Hu Y, Lu J, Lu Y, Qian L, Wang Y, Zhang Y, Liu Q, Xie Y, Guo S, Mehal W, Yu D. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma. Hepatology 2023, 79: 289-306. PMID: 37540187, PMCID: PMC10789383, DOI: 10.1097/hep.0000000000000553.
- Zahrawi F, Fathma S, Mehal W, Banini B. Pharmacologic Management of Obesity after Liver Transplantation: A Critical Review. Annals Of Gastroenterology And Digestive Disorders 2023, 6: 17-25. PMID: 38098758, PMCID: PMC10719957.
- Arumugam S, Li B, Boodapati S, Nathanson M, Sun B, Ouyang X, Mehal W. Mitochondrial DNA and the STING pathway are required for hepatic stellate cell activation. Hepatology 2023, 78: 1448-1461. PMID: 37013923, PMCID: PMC10804318, DOI: 10.1097/hep.0000000000000388.
- New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disordersJamshed F, Dashti F, Ouyang X, Mehal W, Banini B. New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders. World Journal Of Gastroenterology 2023, 29: 1824-1837. PMID: 37032732, PMCID: PMC10080697, DOI: 10.3748/wjg.v29.i12.1824.
- Dashti F, Jamshed F, Ouyang X, Mehal W, Banini B. Digoxin as an emerging therapy in noncardiac diseases. Trends In Pharmacological Sciences 2022, 44: 199-203. PMID: 36396496, DOI: 10.1016/j.tips.2022.10.002.
- Ilagan-Ying Y, Schwartz A, Park E, Bollinger B, Ying L, Mehal W, Do A. S1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating Obesity Medicine for Treatment of Nonalcoholic Fatty Liver Disease. The American Journal Of Gastroenterology 2022, 117: e1043-e1044. DOI: 10.14309/01.ajg.0000862452.53915.0f.
- Ilagan-Ying Y, Valido K, Chehayeb R, Bollinger B, Mehal W, Do A. S1345 Weight Loss Outcomes With and Without Diabetes in Patients With NAFLD in a Specialty Fatty Liver Disease Program. The American Journal Of Gastroenterology 2022, 117: e967-e968. DOI: 10.14309/01.ajg.0000862020.76034.41.
- Ilagan-Ying Y, Cotter R, Bollinger B, Mehal W, Do A. S1358 Nonalcoholic Fatty Liver Disease Outcomes in Patients With Comorbid Psychiatric Disorders Improved by Integrated Medical Weight Management and Hepatology Clinic Care. The American Journal Of Gastroenterology 2022, 117: e975-e976. DOI: 10.14309/01.ajg.0000862072.84358.84.
- Batisti J, Mehal W. Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient. Current Transplantation Reports 2020, 7: 332-339. DOI: 10.1007/s40472-020-00303-0.
- Mankash M, Kelly M, Duffy A, Mehal W, Do A. S1189 Incorporation of Obesity Medicine Into the Care of Patients With Nonalcoholic Fatty Liver Disease: 1-Year Interim Results. The American Journal Of Gastroenterology 2020, 115: s595-s595. DOI: 10.14309/01.ajg.0000706804.10023.a3.
- Mankash M, Kelly M, Mehal W, Do A. S1016 Tolerance and Safety of Meal Replacement Program in Nonalcoholic Steatohepatitis With Fibrosis and Cirrhosis: A Case Series. The American Journal Of Gastroenterology 2020, 115: s518-s519. DOI: 10.14309/01.ajg.0000706112.69854.c1.
- Mankash M, Yousaf M, Duffy A, Mehal W, Do A. S1015 Bariatric Surgery Can Be Performed Safely at Yale-New Haven Hospital in Patients With Cirrhosis. The American Journal Of Gastroenterology 2020, 115: s518-s518. DOI: 10.14309/01.ajg.0000706108.48385.f8.
- Do A, Ilagan-Ying Y, Mehal W. Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports 2019, 18: 444-454. DOI: 10.1007/s11901-019-00498-6.
- Yousaf M, Chaudhary F, Mehal W. The impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Gastroenterology & Hepatology Open Access 2019, 10: 262-266. DOI: 10.15406/ghoa.2019.10.00392.
- Do A, Kuszewski EJ, Langberg K, Mehal W. Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. Hepatology 2019, 70: 1443-1456. PMID: 30991446, PMCID: PMC6783325, DOI: 10.1002/hep.30658.
- Mankash M, Kelly M, Dean J, Duffy A, Mehal W, Do A. 1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model. The American Journal Of Gastroenterology 2019, 114: s599-s599. DOI: 10.14309/01.ajg.0000593756.22484.ae.
- Vijay G, Hu C, Peng J, Garcia-Martinez I, Hoque R, Verghis RM, Ma Y, Mehal W, Shawcross DL, Wen L. Ammonia-Induced Brain Edema Requires Macrophage and T Cell Expression of Toll-Like Receptor 9. Cellular And Molecular Gastroenterology And Hepatology 2019, 8: 609-623. PMID: 31401214, PMCID: PMC6889059, DOI: 10.1016/j.jcmgh.2019.08.002.
- Mehal W, Dioletis E, Paiva R, Secor E, Weiss T, Fields M, Ali A. The Fermented Soy Beverage Q-CAN® Plus Induces Changes in the Oral and Intestinal Microbiome (P20-018-19). Current Developments In Nutrition 2019, 3: nzz040.p20-018-19. PMCID: PMC6574065, DOI: 10.1093/cdn/nzz040.p20-018-19.
- Mehal W, Secor E, Weiss T, Fields M, Leapman M, Ali A. Isoflavone Stability Quality Control Assessment of Q-CAN® Plus, a Novel Fermented Soy Beverage (P12-034-19). Current Developments In Nutrition 2019, 3: 3013530. PMCID: PMC6574992, DOI: 10.1093/cdn/nzz035.p12-034-19.
- Mehal W, Suyavaran A, Dioletis E, Paiva R, Weiss T, Fields M, Ouyang X. Reduction in Serum Levels of Inflammatory Cytokines in Subjects Consuming the Fermented Soy Beverage Q-CAN® Plus (P19-010-19). Current Developments In Nutrition 2019, 3: nzz049.p19-010-19. PMCID: PMC6579392, DOI: 10.1093/cdn/nzz049.p19-010-19.
- Mehal W, Suyavaran A, Dioletis E, Paiva R, Secor E, Weiss T, Fields M, Ouyang X, Ali A. Hematology Safety Data for the Fermented Soy Beverage Q-CAN® Plus (P12-033-19). Current Developments In Nutrition 2019, 3: 3013529. PMCID: PMC6574472, DOI: 10.1093/cdn/nzz035.p12-033-19.
- Mehal W, Dioletis E, Paiva R, Secor E, Weiss T, Fields M, Ouyang X, Ali A. Reduction in Serum Cholesterol in Subjects Consuming the Fermented Soy Beverage Q-CAN® Plus (P06-118-19). Current Developments In Nutrition 2019, 3: nzz031.p06-118-19. PMCID: PMC6576748, DOI: 10.1093/cdn/nzz031.p06-118-19.
- Ouyang X, Mehal W. 894 - Digoxin Protects from Alcoholic Hepatitis and Inhibits TGF-B Induced Fibrotic Response. Gastroenterology 2018, 154: s-1109. DOI: 10.1016/s0016-5085(18)33689-8.
- Chen Y, Yousaf M, Mehal W. Role of sterile inflammation in fatty liver diseases. Liver Research 2018, 2: 21-29. DOI: 10.1016/j.livres.2018.02.003.
- Ouyang X, Han SN, Zhang JY, Dioletis E, Nemeth BT, Pacher P, Feng D, Bataller R, Cabezas J, Stärkel P, Caballeria J, Pongratz RL, Cai SY, Schnabl B, Hoque R, Chen Y, Yang WH, Garcia-Martinez I, Wang FS, Gao B, Torok NJ, Kibbey RG, Mehal WZ. Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis. Cell Metabolism 2018, 27: 339-350.e3. PMID: 29414684, PMCID: PMC5806149, DOI: 10.1016/j.cmet.2018.01.007.
- Vijay G, Hu C, Peng J, Martinez I, Hoque R, Zhang X, Ma Y, Mehal W, Shawcross D, Wen L. Ammonia Mediated Brain-oedema and Immune Dysfunction is Mediated by Toll-like Receptor (TLR) 9. Journal Of Clinical And Experimental Hepatology 2017, 7: s2-s3. DOI: 10.1016/j.jceh.2017.01.004.
- Vijay G, Hu C, Peng J, Martinez I, Hoque R, Zhang X, Ma Y, Mehal W, Shawcross D, Wen L. THU-418 Ammonia-Induced Brain Oedema and Immune Dysfunction is Mediated by Toll-Like Receptor 9 (TLR9). Journal Of Hepatology 2016, 64: s314. DOI: 10.1016/s0168-8278(16)00420-7.
- Farooq A, Farooq A, Mehal W. Aspartate a New Treatment Modality in the Treatment of Acute Liver Failure and Actiminophen-Induced Toxicity. The American Journal Of Gastroenterology 2015, 110: s895. DOI: 10.14309/00000434-201510001-02147.
- Mehal W, Schuppan D. Antifibrotic Therapies in the Liver. Seminars In Liver Disease 2015, 35: 184-198. PMID: 25974903, PMCID: PMC5743222, DOI: 10.1055/s-0035-1550055.
- Ouyang X, Zhang J, Feng D, Cai S, Protiva P, Garcia-Martinez I, Wang F, Gao B, Mehal W. Su1058 Low Dose Digoxin Protects From NASH and Alcoholic Hepatitis in Mice by Inhibiting Inflammasome Activity and Mitochondrial ROS Production. Gastroenterology 2015, 148: s-1052. DOI: 10.1016/s0016-5085(15)33588-5.
- Garcia-Martinez I, Santoro N, Chen Y, Ouyang X, Caprio S, Coffman R, Candia A, Mehal W. 237 Humans and Mice With NASH Have Increased Plasma Levels of TLR9 Ligand, and a TLR7/9 Bifunctional Antagonist Reduces NASH in Mice. Gastroenterology 2015, 148: s-974. DOI: 10.1016/s0016-5085(15)33328-x.
- Ghani A, Mehal W, Ali A. Food Reactivity on the ALCAT Leukocyte Activation Test Is Associated with Upregulation of CD11b on T Cells. Journal Of Alternative And Complementary Medicine 2014, 20: a35-a36. DOI: 10.1089/acm.2014.5089.abstract.
- Mehal WZ. Who is the scientist in bio-medical research, the author or the reviewer? Frontiers In Pharmacology 2014, 5: 50. PMID: 24723888, PMCID: PMC3972448, DOI: 10.3389/fphar.2014.00050.
- Hoque R, Farooq A, Ghani A, Gorelick F, Mehal WZ. Lactate Reduces Liver and Pancreatic Injury in Toll-Like Receptor– and Inflammasome-Mediated Inflammation via GPR81-Mediated Suppression of Innate Immunity. Gastroenterology 2014, 146: 1763-1774. PMID: 24657625, PMCID: PMC4104305, DOI: 10.1053/j.gastro.2014.03.014.
- Ouyang X, Ghani A, Malik A, Wilder T, Colegio OR, Flavell RA, Cronstein BN, Mehal WZ. Adenosine is required for sustained inflammasome activation via the A2A receptor and the HIF-1α pathway. Nature Communications 2013, 4: 2909. PMID: 24352507, PMCID: PMC3895487, DOI: 10.1038/ncomms3909.
- Gao B, Friedman S, Mehal W. The Immunopathogenesis of Cirrhosis. 2013, 413-424. DOI: 10.1007/978-3-319-02096-9_28.
- Mehal WZ. The Gordian Knot of dysbiosis, obesity and NAFLD. Nature Reviews Gastroenterology & Hepatology 2013, 10: 637-644. PMID: 23958600, DOI: 10.1038/nrgastro.2013.146.
- Kubes P, Mehal WZ. Sterile Inflammation in the Liver. Gastroenterology 2012, 143: 1158-1172. PMID: 22982943, DOI: 10.1053/j.gastro.2012.09.008.
- Mehal W, Imaeda A. Cell Death and Fibrogenesis. Seminars In Liver Disease 2010, 30: 226-231. PMID: 20665375, PMCID: PMC3219753, DOI: 10.1055/s-0030-1255352.
- Sohail M, Malik A, Hoque R, Mehal W. 239 P2X7 Receptor Activation up-Stream of the NLRP3 Inflammasome is Required for APAP Hepatotoxicity in Mice. Gastroenterology 2010, 138: s-781. DOI: 10.1016/s0016-5085(10)63599-8.
- Sohail M, Husain S, Hoque R, Malik A, Shah A, Mehal W. M1674 Caspase-1 and TLR-7,9 Signaling are Required for Cerulein Pancreatitis. Gastroenterology 2010, 138: s-827. DOI: 10.1016/s0016-5085(10)63811-5.
- Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M, Sutterwala FS, Flavell RA, Mehal WZ. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. Journal Of Clinical Investigation 2009, 119: 305-314. PMID: 19164858, PMCID: PMC2631294, DOI: 10.1172/jci35958.
- Sohail M, Watanabe A, Mahmood S, Hashmi A, Hakim W, Mehal W. M1578 Adenosine Induces Loss of Actin Stress Fibers and Inhibits Contraction in Hepatic Stellate Cells Via Rho Inhibition. Gastroenterology 2008, 134: a-797. DOI: 10.1016/s0016-5085(08)63725-7.
- Mahmood S, Watanabe A, Sohail M, Flavell R, Mehal W. 56 Aacetaminophen Hepatotoxicity Is Dependent On TLR9 and Can Be Reduced By a TLR9 Antagonist. Gastroenterology 2008, 134: a-752. DOI: 10.1016/s0016-5085(08)63514-3.
- Imaeda A, Sutterwala F, Watanabe A, Mahmood S, Sohail M, Flavell R, Mehal W. 467 Aspirin Blocks Acetaminophen Induced Hepatotoxicity and Mortality in Mice - Dependent On the ASC/Caspase-1 Inflammasome. Gastroenterology 2008, 134: a-767. DOI: 10.1016/s0016-5085(08)63581-7.
- Mohamadnejad M, Sohail M, Swenson E, Mehal W. T1773 Adenosine Inhibits Hepatocyte Growth Factor Induced Chemotaxis in Mesenchymal Stem Cells. Gastroenterology 2008, 134: a-819. DOI: 10.1016/s0016-5085(08)63829-9.
- Mehal W, Friedman S. The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis. 2007, 111-121. DOI: 10.1007/978-1-59745-518-3_10.
- Mehal W. The Clinician's Guide to Liver Disease. Journal Of Clinical Gastroenterology 2006, 40: 564. DOI: 10.1097/00004836-200607000-00027.
- Qamar A, Sheikh S, Inayat I, Mehal W. 213 Leptin protects stellate cells, but not hepatocytes, from CD95 mediated apoptosis. Hepatology 2003, 38: 259. DOI: 10.1016/s0270-9139(03)80256-2.
- Mehal W, Azzaroli F, Crispe I. Antigen Presentation by Liver Cells Controls Intrahepatic T Cell Trapping, Whereas Bone Marrow-Derived Cells Preferentially Promote Intrahepatic T Cell Apoptosis. The Journal Of Immunology 2001, 167: 667-673. PMID: 11441069, DOI: 10.4049/jimmunol.167.2.667.
- Dao T, Exley M, Mehal W, Tahir S, Snapper S, Taniguchi M, Balk S, Crispe I. Involvement of CD1 in Peripheral Deletion of T Lymphocytes Is Independent of NK T Cells. The Journal Of Immunology 2001, 166: 3090-3097. PMID: 11207260, DOI: 10.4049/jimmunol.166.5.3090.
- Mehal W, Azzaroli F, Crispe I. Immunology of the healthy liver: Old questions and new insights. Gastroenterology 2001, 120: 250-260. PMID: 11208734, DOI: 10.1053/gast.2001.20947.
- Theise N, Krause D, Mehal W, Illei P. Reply. Hepatology 2000, 32: 1181. DOI: 10.1016/s0270-9139(00)80044-0.
- Crispe I, Dao T, Klugewitz K, Mehal W, Metz D. The liver as a site of T‐cell apoptosis: graveyard, or killing field? Immunological Reviews 2000, 174: 47-62. PMID: 10807506, DOI: 10.1034/j.1600-0528.2002.017412.x.
- Mehal W, Juedes A, Crispe I. Selective retention of activated CD8+ T cells by the normal liver. The Journal Of Immunology 1999, 163: 3202-10. PMID: 10477588, DOI: 10.4049/jimmunol.163.6.3202.
- Conte H, Chen Y, Mehal W, Phil D, Scinto J, Quagliarello V. A prognostic rule for elderly patients admitted with community-acquired pneumonia. The American Journal Of Medicine 1999, 106: 20-28. PMID: 10320113, DOI: 10.1016/s0002-9343(98)00369-6.
- Dao T, Mehal W, Crispe I. IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. The Journal Of Immunology 1998, 161: 2217-22. PMID: 9725214, DOI: 10.4049/jimmunol.161.5.2217.
- Mehal W, Crispe I. TCR ligation on CD8+ T cells creates double-negative cells in vivo. The Journal Of Immunology 1998, 161: 1686-93. PMID: 9712032, DOI: 10.4049/jimmunol.161.4.1686.
- Crispe I, Mehal W. Strange brew: T cells in the liver. Trends In Immunology 1996, 17: 522-525. PMID: 8961629, DOI: 10.1016/s0167-5699(96)80906-6.
Locations
1
Yale Digestive Disorders
Yale New Haven Hospital
20 York Street
New Haven, CT 06510
1 of 3
- Yale Digestive DisordersYale New Haven Hospital20 York StreetNew Haven, CT 06510
- Old Saybrook Medical Center633 Middlesex TurnpikeOld Saybrook, CT 06475
- 8 Devine StreetNorth Haven, CT 06473
1
Yale Digestive Disorders
Yale New Haven Hospital
20 York Street
New Haven, CT 06510
1 of 3
- Yale Digestive DisordersYale New Haven Hospital20 York StreetNew Haven, CT 06510
- Old Saybrook Medical Center633 Middlesex TurnpikeOld Saybrook, CT 06475
- 8 Devine StreetNorth Haven, CT 06473